Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Liu, Qinwen"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 59
Tytuł:
Screening of the key response component groups and mechanism verification of Huangqi-Guizhi-Wuwu-Decoction in treating rheumatoid arthritis based on a novel computational pharmacological model
Autorzy:
Liu, QinwenAff1, Aff2
Luo, QianAff1, Aff2
Fan, QilingAff1, Aff2
Li, YiAff1, Aff2
Lu, AipingAff3, Aff4, IDs1290602304315y_cor5
Guan, DaogangAff1, Aff2, IDs1290602304315y_cor6
Pokaż więcej
Źródło:
BMC Complementary Medicine and Therapies. 24(1)
Czasopismo naukowe
Szczegóły
Tytuł:
A novel network pharmacology strategy to decode mechanism of Wuling Powder in treating liver cirrhosis
Autorzy:
Liu, QinwenAff1, Aff2
Li, XiaoweiAff1, Aff2
Li, YiAff1, Aff2
Luo, QianAff1, Aff2
Fan, QilingAff1, Aff2
Lu, AipingAff5, Aff6, IDs1302002400896z_cor6
Guan, DaogangAff1, Aff2, IDs1302002400896z_cor7
Li, JiahuiAff1, Aff3, Aff4, IDs1302002400896z_cor8
Pokaż więcej
Źródło:
Chinese Medicine. 19(1)
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Analytical validation of a multi-cancer early detection test with cancer signal origin using a cell-free DNA-based targeted methylation assay.
Autorzy:
Alexander GE; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Lin W; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Ortega FE; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Ramaiah M; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Jung B; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Ji L; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Revenkova E; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Shah P; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Croisetiere C; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Berman JR; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Eubank L; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Naik G; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Brooks J; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Mich A; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Shojaee S; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Ronaghi N; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Chawla H; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Hou X; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Liu Q; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Yakym CAV; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Moradi PW; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Halks-Miller M; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Aravanis AM; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Parpart-Li S; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Hunkapiller N; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Apr 14; Vol. 18 (4), pp. e0283001. Date of Electronic Publication: 2023 Apr 14 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cell-Free Nucleic Acids*/genetics
Neoplasms*/diagnosis
Neoplasms*/genetics
Sensitivity and Specificity ; Early Detection of Cancer ; Reproducibility of Results ; DNA Methylation/genetics ; Biomarkers, Tumor/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Contribution analysis of vibration transmission path of planetary reducer box based on velocity involvement loss.
Autorzy:
Li, Miaomiao (AUTHOR)
Liu, Qinwen (AUTHOR)
Zhu, Shixuan (AUTHOR)
Ai, Sheng (AUTHOR)
Chen, Weifang (AUTHOR)
Zhu, Rupeng (AUTHOR)
Pokaż więcej
Źródło:
Journal of Low Frequency Noise, Vibration & Active Control. Mar2023, Vol. 42 Issue 1, p39-53. 15p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Evaluation of cell-free DNA approaches for multi-cancer early detection.
Autorzy:
Jamshidi, Arash (AUTHOR)
Liu, Minetta C. (AUTHOR)
Klein, Eric A. (AUTHOR)
Venn, Oliver (AUTHOR)
Hubbell, Earl (AUTHOR)
Beausang, John F. (AUTHOR)
Gross, Samuel (AUTHOR)
Melton, Collin (AUTHOR)
Fields, Alexander P. (AUTHOR)
Liu, Qinwen (AUTHOR)
Zhang, Nan (AUTHOR)
Fung, Eric T. (AUTHOR)
Kurtzman, Kathryn N. (AUTHOR)
Amini, Hamed (AUTHOR)
Betts, Craig (AUTHOR)
Civello, Daniel (AUTHOR)
Freese, Peter (AUTHOR)
Calef, Robert (AUTHOR)
Davydov, Konstantin (AUTHOR)
Fayzullina, Saniya (AUTHOR)
Pokaż więcej
Źródło:
Cancer Cell. Dec2022, Vol. 40 Issue 12, p1537-1537. 1p.
Czasopismo naukowe
Szczegóły
Tytuł:
An Integrative Pharmacology Model for Decoding the Underlying Therapeutic Mechanisms of Ermiao Powder for Rheumatoid Arthritis.
Autorzy:
Wu, Jie
Wang, Kexin
Liu, Qinwen
Li, Yi
Huang, Yingying
Liu, Yujie
Cai, Jieqi
Yin, Chuanhui
Li, Xiaowei
Yu, Hailang
Meng, Wei
Wang, Handuo
Lu, Aiping
Li, Yazi
Guan, Daogang
Pokaż więcej
Temat:
RHEUMATOID arthritis
MITOGEN-activated protein kinases
CHINESE medicine
TUMOR necrosis factors
POWDERS
NF-kappa B
Źródło:
Frontiers in Pharmacology; 2/23/2022, Vol. 13, p1-18, 18p
Czasopismo naukowe
Szczegóły
Tytuł:
Maprotiline Suppresses Cholesterol Biosynthesis and Hepatocellular Carcinoma Progression Through Direct Targeting of CRABP1.
Autorzy:
Zheng, Cancan
Zhu, Yidong
Liu, Qinwen
Luo, Tingting
Xu, Wenwen
Pokaż więcej
Temat:
STEROL regulatory element-binding proteins
HEPATOCELLULAR carcinoma
BIOSYNTHESIS
CHOLESTEROL
SMALL molecules
Źródło:
Frontiers in Pharmacology; 5/20/2021, Vol. 11, p1-12, 12p
Przedsiębiorstwo/ jednostka:
UNITED States. Food & Drug Administration
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 59

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies